Analysts' Top Healthcare Picks: Stryker (SYK), Foghorn Therapeutics (FHTX)
Insiders Sold Foghorn Therapeutics At US$6.56, Meanwhile Stock Sits Near US$5.53
Even though Foghorn Therapeutics Inc. (NASDAQ:FHTX) has fallen by 31% over the past week , insiders who sold US$72k worth of stock over the past year have had less luck.
Press Release: Foghorn Therapeutics Strengthens Financial Leadership With Appointment of Kristian Humer as Chief Financial Officer
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn(R) Therapeutics Inc. (
Foghorn Therapeutics Price Target Maintained With a $13.00/Share by Wedbush
Foghorn Therapeutics Price Target Maintained With a $13.00/Share by Wedbush
Foghorn Therapeutics: Buy Rating Affirmed Amidst Promising Pipeline and Strategic Alliances
HC Wainwright & Co. : The Foghorn Therapeutics (FHTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
HC Wainwright & Co. : The Foghorn Therapeutics (FHTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $20 price target.
Foghorn Therapeutics Unveils Cancer Research Breakthroughs
Foghorn Therapeutics Presents New Preclinical Data On FHD-909,; Says 'FHD-909 Demonstrated Favorable Tolerability and Dose-dependent Single Agent Activity in BRG1 Mutated Cancers Preclinically'
Foghorn Therapeutics Presents New Preclinical Data On FHD-909,; Says 'FHD-909 Demonstrated Favorable Tolerability and Dose-dependent Single Agent Activity in BRG1 Mutated Cancers Preclinically'
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) today announced new preclinical data for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, selective CBP degrader, and selective EP300 degrader programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting. Foghorn management will hold a conference call and webcast today at 5 p.m. ET to review important pipeline updates.
Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction With the 2024 AACR Annual Meeting
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs Conference
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
Foghorn Therapeutics(FHTX.US) Officer Sells US$72,133.6 in Common Stocks
$Foghorn Therapeutics(FHTX.US)$ Officer Cavalie Fanny sold 11,000 shares of Common Stocks on Mar 11, 2024 at an average price of $6.5576 for a total value of $72,133.6.Source: Announcement What is sta
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Analysts Just Slashed This Year's Estimates
The analysts covering Foghorn Therapeutics Inc. (NASDAQ:FHTX) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Reven
Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $13 Price Target
Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $13 price target.
Foghorn Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/08/2024 80.56% Wedbush → $13 Reiterates Outperform → Outperform 11/13/2023 -16.67% Morgan Stanley $10 →
Foghorn Therapeutics' FHD-286: A Promising Contender in AML Treatment and Overcoming TKI Resistance
Foghorn Therapeutics: Q4 Earnings Insights
Foghorn Therapeutics (NASDAQ:FHTX) reported its Q4 earnings results on Thursday, March 7, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsFoghorn Therapeutics beat e
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
No Data